Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1298-1300

  Cutler, Neal R ^a   Vincent, John ^b   Jhee, Stanford S ^a   Teng, Renli ^b   Wardle, Tom ^a   Lucas, Gerri ^a   Dogolo, L C ^b   Sramek, John J ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CEREBROSPINAL FLUID; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG POTENCY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR PUNCTURE; MALE; NAUSEA; PRIORITY JOURNAL; RASH; VERTIGO;

EID: 0030919183     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1298     Document Type: Article

References (14)

1. Briggs Gooding, B., and R. N. Jones. 1993. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob. Agents Chemother. 37:349-353.
2. Bruce, J., L. Tamarkin, C. Riedel, S. Markey, and E. H. Oldfield. 1991. Sequential cerebrospinal fluid and plasma sampling in humans: 24-hour melatonin measurements in normal subjects and after peripheral sympathectomy. J. Clin. Endocrinol. Metab. 72:819-823.
3. Bruce, J. N., and E. H. Oldfield. 1988. Method for sequential sampling of cerebrospinal fluid in humans. Neurosurgery 23:788-790.
4. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
5. Metropolitan Life Insurance Company. 1983. 1983 Metropolitan Life Insurance height and weight tables. Stat. Bull. Metrop. Co. 64:3-9.
6. Nau, R., T. Schmidt, K. Kaye, J. L. Froula, and M. G. Tauber. 1995. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 39:593-597.
7. Paris, M. M., S. M. Hickey, M. Trujillo, S. Shelton, and G. H. McCracken, Jr. 1995. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 39:1243-1246.
8. Spangler, S. K., M. R. Jacobs, and P. C. Applebaum. 1994. Activity of CP-99,219 compared to those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
9. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36:385-394.
10. Teng, R., T. E. Liston, and S. C. Harris. 1996. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J. Antimicrob. Chemother. 37:955-963.
11. Teng, R., T. G. Tensfeldt, T. E. Liston, and G. Foulds. 1996. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. J. Chromatogr. 675: 53-59.
12. von Rosenstiel, N., and D. Adam. 1994. Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs 47:872-901.
13. Walker, R. C., and A. J. Wright. 1991. The fluoroquinolones. Mayo Clin. Proc. 66:1249-1259.
14. Wolfson, J. S., and D. C. Hooper. 1991. Overview of fluoroquinolone safety. Am. J. Med. 91(Suppl. 6A):S153-S161.